National Pension Service Has $74.81 Million Stock Holdings in IDEXX Laboratories, Inc. $IDXX

National Pension Service grew its holdings in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 2.4% in the 3rd quarter, according to its most recent disclosure with the SEC. The fund owned 117,093 shares of the company’s stock after acquiring an additional 2,715 shares during the period. National Pension Service owned about 0.15% of IDEXX Laboratories worth $74,810,000 as of its most recent SEC filing.

Other institutional investors also recently modified their holdings of the company. AlphaQuest LLC raised its position in shares of IDEXX Laboratories by 112.3% during the third quarter. AlphaQuest LLC now owns 845 shares of the company’s stock worth $540,000 after acquiring an additional 447 shares during the last quarter. Arizona State Retirement System increased its position in IDEXX Laboratories by 0.3% during the 3rd quarter. Arizona State Retirement System now owns 23,731 shares of the company’s stock valued at $15,161,000 after purchasing an additional 68 shares during the period. Fidelis Capital Partners LLC raised its holdings in IDEXX Laboratories by 2.6% during the 3rd quarter. Fidelis Capital Partners LLC now owns 797 shares of the company’s stock worth $509,000 after purchasing an additional 20 shares during the last quarter. New York State Common Retirement Fund raised its stake in IDEXX Laboratories by 6.8% during the third quarter. New York State Common Retirement Fund now owns 60,225 shares of the company’s stock worth $38,477,000 after buying an additional 3,820 shares during the last quarter. Finally, TD Waterhouse Canada Inc. boosted its position in IDEXX Laboratories by 37.9% during the third quarter. TD Waterhouse Canada Inc. now owns 593 shares of the company’s stock valued at $366,000 after acquiring an additional 163 shares during the last quarter. Institutional investors own 87.84% of the company’s stock.

IDEXX Laboratories Trading Down 0.9%

Shares of IDEXX Laboratories stock opened at $670.46 on Monday. The firm has a market cap of $53.54 billion, a PE ratio of 53.17, a PEG ratio of 3.58 and a beta of 1.67. The company has a debt-to-equity ratio of 0.24, a current ratio of 1.18 and a quick ratio of 0.87. IDEXX Laboratories, Inc. has a 1 year low of $356.14 and a 1 year high of $769.98. The company has a 50 day simple moving average of $705.35 and a two-hundred day simple moving average of $661.79.

IDEXX Laboratories (NASDAQ:IDXX) last announced its quarterly earnings results on Monday, November 3rd. The company reported $3.22 EPS for the quarter, topping analysts’ consensus estimates of $3.14 by $0.08. IDEXX Laboratories had a return on equity of 67.78% and a net margin of 24.65%.The business had revenue of $1.11 billion for the quarter, compared to analysts’ expectations of $1.07 billion. During the same period in the previous year, the firm earned $2.80 EPS. The business’s quarterly revenue was up 13.3% on a year-over-year basis. Analysts expect that IDEXX Laboratories, Inc. will post 11.93 earnings per share for the current fiscal year.

Insider Buying and Selling at IDEXX Laboratories

In related news, EVP Nimrata Hunt sold 9,425 shares of the firm’s stock in a transaction on Friday, November 7th. The stock was sold at an average price of $703.34, for a total value of $6,628,979.50. Following the completion of the sale, the executive vice president owned 21,149 shares of the company’s stock, valued at $14,874,937.66. This trade represents a 30.83% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this link. Corporate insiders own 0.98% of the company’s stock.

Analyst Upgrades and Downgrades

Several analysts have recently weighed in on IDXX shares. Barclays assumed coverage on shares of IDEXX Laboratories in a research note on Monday, December 8th. They issued an “overweight” rating and a $850.00 price objective for the company. Morgan Stanley increased their price target on IDEXX Laboratories from $765.00 to $805.00 and gave the stock an “overweight” rating in a report on Tuesday, November 4th. Wall Street Zen cut IDEXX Laboratories from a “strong-buy” rating to a “buy” rating in a research report on Saturday, January 17th. Leerink Partners set a $785.00 price objective on shares of IDEXX Laboratories in a report on Monday, November 3rd. Finally, Weiss Ratings cut shares of IDEXX Laboratories from a “buy (b-)” rating to a “hold (c+)” rating in a report on Thursday. Seven research analysts have rated the stock with a Buy rating and four have issued a Hold rating to the stock. According to MarketBeat.com, IDEXX Laboratories presently has an average rating of “Moderate Buy” and an average price target of $763.50.

IDEXX Laboratories Profile

IDEXX Laboratories, Inc (NASDAQ: IDXX) is a global developer, manufacturer and provider of diagnostic products and services primarily for the animal health, water testing and food safety markets. Headquartered in Westbrook, Maine, the company supplies in-clinic diagnostic instruments, consumables, reference laboratory testing and practice-management tools that support veterinarians, livestock and dairy producers, and utilities and food producers worldwide.

IDEXX’s product portfolio includes point-of-care tests and immunoassays designed for rapid diagnosis in veterinary clinics, in-clinic chemistry and hematology analyzers, automated urinalysis systems, and digital diagnostic solutions.